Literature DB >> 12032100

Aspirin use and counseling about aspirin among patients with diabetes.

Sarah L Krein1, Sandeep Vijan, Leonard M Pogach, Mary M Hogan, Eve A Kerr.   

Abstract

OBJECTIVE: Despite being a safe, effective therapy for lowering cardiovascular risk, only 20% of diabetic patients were using aspirin in the early 1990s. This study examines current physician practices and the use of aspirin therapy by individuals with diabetes. RESEARCH DESIGN AND METHODS: A random sample of diabetic patients receiving care in the Department of Veterans Affairs health care system were surveyed during January-March 2000. The association between aspirin counseling, aspirin use, and reported coronary vascular disease (CVD) and classical CVD risk factors were examined using logistic regression. The effect of increasing aspirin use on risk of myocardial infarction (MI) and cardiovascular mortality was demonstrated by simulation.
RESULTS: Seventy-one percent of respondents reported being counseled about aspirin use, and 66% were taking daily aspirin. Individuals with known CVD were more likely to be counseled (odds ratio [OR] 4.9, 95% CI 2.9-8.1) and to use aspirin (2.1, 1.2-3.7). The factor most strongly associated with aspirin use was having been counseled about aspirin therapy by a doctor. We estimate that for this population, increasing daily aspirin use to 90% could prevent an additional 11,000 MIs and potentially save >8,000 lives.
CONCLUSIONS: Compared with previous reports, a substantial proportion of these diabetic patients have been counseled about and use aspirin. Most clinicians recognize aspirin as an important treatment for patients with preexisting coronary disease. However, since diabetes is now considered a CVD equivalent, it is imperative that clinicians include counseling about aspirin therapy as a care priority for all their diabetic patients, as this simple intervention may prevent many cardiovascular events and deaths.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12032100     DOI: 10.2337/diacare.25.6.965

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  4 in total

1.  Lipid lowering targets are easier to attain than those for treatment of hypertension in type 2 diabetes.

Authors:  M Sherlock; D Mylotte; J Mac Mahon; K B Moore; C J Thompson
Journal:  Ir J Med Sci       Date:  2006 Oct-Dec       Impact factor: 1.568

2.  Psychoneuroimmune implications of type 2 diabetes: redux.

Authors:  Jason C O'Connor; Daniel R Johnson; Gregory G Freund
Journal:  Immunol Allergy Clin North Am       Date:  2009-05       Impact factor: 3.479

3.  Prevalence of antiplatelet therapy in patients with diabetes.

Authors:  Shaun R Miller; Benjamin Littenberg; Charles D MacLean
Journal:  Cardiovasc Diabetol       Date:  2005-12-01       Impact factor: 9.951

4.  Prescription of Aspirin for adults with Diabetes.

Authors:  P Sabitha; Asha Kamath; Prabha M Adhikari
Journal:  Int J Diabetes Dev Ctries       Date:  2008-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.